Mutations in glioblastoma oncosuppressive pathways pave the way for oncomodulatory activity of cytomegalovirus

OncoImmunology

Volumn 2, Issue 9, 2013, Pages

  Hollon, Todd C ^a   Price, Richard L ^b   Kwon, Chang Hyuk ^b,c   Chiocca, E Antonio ^d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Brain tumor; Glioma; Rhabdomyosarcoma; Tumor suppressor genes; Viral oncology

Indexed keywords

ANGIOGENESIS INHIBITOR; IMMUNOMODULATING AGENT; ONCOLYTIC VIRUS; STAT3 PROTEIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE EXACERBATION; GENE DELIVERY SYSTEM; GENE MUTATION; GENE PRODUCT; GLIOBLASTOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; MALIGNANT TRANSFORMATION; MICROBIAL ACTIVITY; NONHUMAN; OVERALL SURVIVAL; RHABDOMYOSARCOMA; TUMOR IMMUNITY; VIRUS CARCINOGENESIS;

EID: 84890285094     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25620     Document Type: Article

References (10)

1. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002; 62:3347-50; PMID:12067971
2. Sampson JH, Mitchell DA. Is cytomegalovirus a therapeutic target in glioblastoma? Clin Cancer Res 2011; 17:4619-21; PMID:21632859; http://dx.doi. org/10.1158/1078-0432.CCR-11-0992
3. Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 2009; 11:1-9; PMID:19107226
4. Price RL, Song J, Bingmer K, Kim TH, Yi JY, Nowicki MO, et al. Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res 2013; 73:3441-50; PMID:23729642; http://dx.doi.org/10.1158/0008-5472.CAN-12-3846
5. Price RL, Bingmer K, Harkins L, Iwenofu OH, Kwon CH, Cook C, et al. Cytomegalovirus infection leads to pleomorphic rhabdomyosarcomas in Trp53+/- mice. Cancer Res 2012; 72:5669-74; PMID:23002204; http://dx.doi.org/10.1158/0008-5472.CAN-12-2425
6. Brantley EC, Benveniste EN. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 2008; 6:675-84; PMID:18505913; http://dx.doi. org/10.1158/1541-7786.MCR-07-2180
7. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-8; PMID:18772890; http://dx.doi. org/10.1038/nature07385
8. Slinger E, Maussang D, Schreiber A, Siderius M, Rahbar A, Fraile-Ramos A, et al. HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal 2010; 3:ra58; PMID:20682912; http://dx.doi.org/10.1126/ scisignal.2001180
9. Soroceanu L, Matlaf L, Bezrookove V, Harkins L, Martinez R, Greene M, et al. Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. Cancer Res 2011; 71:6643-53; PMID:21900396; http://dx.doi.org/10.1158/0008- 5472.CAN-11-0744
10. Soroceanu L, Akhavan A, Cobbs CS. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 2008; 455:391-5; PMID:18701889; http://dx.doi. org/10.1038/nature07209